Risk of Gastrointestinal Bleeding with Rivaroxaban: A Comparative Study with Warfarin

Muhammed Sherid, Samian Sulaiman, Salih Samo, Husein Husein, Ruth Tupper, Charles Spurr, Humberto Sifuentes, Subbaramiah Sridhar

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Introduction. The risk of gastrointestinal (GI) bleeding with rivaroxaban has not been studied extensively. The aim of our study was to assess this risk in comparison to warfarin. Methods. We examined the medical records for patients who were started on rivaroxaban or warfarin from April 2011 to April 2013. Results. We identified 300 patients (147 on rivaroxaban versus 153 on warfarin). GI bleeding occurred in 4.8% patients with rivaroxaban when compared to 9.8% patients in warfarin group (p = 0.094). GI bleeding occurred in 8% with therapeutic doses of rivaroxaban (>10 mg/d) compared to 9.8% with warfarin (p = 0.65). Multivariate analysis showed that patients who were on rivaroxaban for ≤40 days had a higher incidence of GI bleeding than those who were on it for >40 days (OR = 2.8, p = 0.023). Concomitant use of dual antiplatelet agents was associated with increased risk of GI bleeding in the rivaroxaban group (OR = 7.4, p = 0.0378). Prior GI bleeding was also a risk factor for GI bleeding in rivaroxaban group (OR = 15.5). Conclusion. The incidence of GI bleeding was similar between rivaroxaban and warfarin. The risk factors for GI bleeding with rivaroxaban were the first 40 days of taking the drug, concomitant dual antiplatelet agents, and prior GI bleeding.

Original languageEnglish (US)
Article number9589036
JournalGastroenterology Research and Practice
Volume2016
DOIs
StatePublished - Jan 1 2016

Fingerprint

Warfarin
Hemorrhage
Platelet Aggregation Inhibitors
Rivaroxaban
Incidence
Medical Records
Multivariate Analysis

ASJC Scopus subject areas

  • Hepatology
  • Gastroenterology

Cite this

Risk of Gastrointestinal Bleeding with Rivaroxaban : A Comparative Study with Warfarin. / Sherid, Muhammed; Sulaiman, Samian; Samo, Salih; Husein, Husein; Tupper, Ruth; Spurr, Charles; Sifuentes, Humberto; Sridhar, Subbaramiah.

In: Gastroenterology Research and Practice, Vol. 2016, 9589036, 01.01.2016.

Research output: Contribution to journalArticle

Sherid, Muhammed ; Sulaiman, Samian ; Samo, Salih ; Husein, Husein ; Tupper, Ruth ; Spurr, Charles ; Sifuentes, Humberto ; Sridhar, Subbaramiah. / Risk of Gastrointestinal Bleeding with Rivaroxaban : A Comparative Study with Warfarin. In: Gastroenterology Research and Practice. 2016 ; Vol. 2016.
@article{9cbef67d07b040a5bfcc58a2ec269795,
title = "Risk of Gastrointestinal Bleeding with Rivaroxaban: A Comparative Study with Warfarin",
abstract = "Introduction. The risk of gastrointestinal (GI) bleeding with rivaroxaban has not been studied extensively. The aim of our study was to assess this risk in comparison to warfarin. Methods. We examined the medical records for patients who were started on rivaroxaban or warfarin from April 2011 to April 2013. Results. We identified 300 patients (147 on rivaroxaban versus 153 on warfarin). GI bleeding occurred in 4.8{\%} patients with rivaroxaban when compared to 9.8{\%} patients in warfarin group (p = 0.094). GI bleeding occurred in 8{\%} with therapeutic doses of rivaroxaban (>10 mg/d) compared to 9.8{\%} with warfarin (p = 0.65). Multivariate analysis showed that patients who were on rivaroxaban for ≤40 days had a higher incidence of GI bleeding than those who were on it for >40 days (OR = 2.8, p = 0.023). Concomitant use of dual antiplatelet agents was associated with increased risk of GI bleeding in the rivaroxaban group (OR = 7.4, p = 0.0378). Prior GI bleeding was also a risk factor for GI bleeding in rivaroxaban group (OR = 15.5). Conclusion. The incidence of GI bleeding was similar between rivaroxaban and warfarin. The risk factors for GI bleeding with rivaroxaban were the first 40 days of taking the drug, concomitant dual antiplatelet agents, and prior GI bleeding.",
author = "Muhammed Sherid and Samian Sulaiman and Salih Samo and Husein Husein and Ruth Tupper and Charles Spurr and Humberto Sifuentes and Subbaramiah Sridhar",
year = "2016",
month = "1",
day = "1",
doi = "10.1155/2016/9589036",
language = "English (US)",
volume = "2016",
journal = "Gastroenterology Research and Practice",
issn = "1687-6121",
publisher = "Hindawi Publishing Corporation",

}

TY - JOUR

T1 - Risk of Gastrointestinal Bleeding with Rivaroxaban

T2 - A Comparative Study with Warfarin

AU - Sherid, Muhammed

AU - Sulaiman, Samian

AU - Samo, Salih

AU - Husein, Husein

AU - Tupper, Ruth

AU - Spurr, Charles

AU - Sifuentes, Humberto

AU - Sridhar, Subbaramiah

PY - 2016/1/1

Y1 - 2016/1/1

N2 - Introduction. The risk of gastrointestinal (GI) bleeding with rivaroxaban has not been studied extensively. The aim of our study was to assess this risk in comparison to warfarin. Methods. We examined the medical records for patients who were started on rivaroxaban or warfarin from April 2011 to April 2013. Results. We identified 300 patients (147 on rivaroxaban versus 153 on warfarin). GI bleeding occurred in 4.8% patients with rivaroxaban when compared to 9.8% patients in warfarin group (p = 0.094). GI bleeding occurred in 8% with therapeutic doses of rivaroxaban (>10 mg/d) compared to 9.8% with warfarin (p = 0.65). Multivariate analysis showed that patients who were on rivaroxaban for ≤40 days had a higher incidence of GI bleeding than those who were on it for >40 days (OR = 2.8, p = 0.023). Concomitant use of dual antiplatelet agents was associated with increased risk of GI bleeding in the rivaroxaban group (OR = 7.4, p = 0.0378). Prior GI bleeding was also a risk factor for GI bleeding in rivaroxaban group (OR = 15.5). Conclusion. The incidence of GI bleeding was similar between rivaroxaban and warfarin. The risk factors for GI bleeding with rivaroxaban were the first 40 days of taking the drug, concomitant dual antiplatelet agents, and prior GI bleeding.

AB - Introduction. The risk of gastrointestinal (GI) bleeding with rivaroxaban has not been studied extensively. The aim of our study was to assess this risk in comparison to warfarin. Methods. We examined the medical records for patients who were started on rivaroxaban or warfarin from April 2011 to April 2013. Results. We identified 300 patients (147 on rivaroxaban versus 153 on warfarin). GI bleeding occurred in 4.8% patients with rivaroxaban when compared to 9.8% patients in warfarin group (p = 0.094). GI bleeding occurred in 8% with therapeutic doses of rivaroxaban (>10 mg/d) compared to 9.8% with warfarin (p = 0.65). Multivariate analysis showed that patients who were on rivaroxaban for ≤40 days had a higher incidence of GI bleeding than those who were on it for >40 days (OR = 2.8, p = 0.023). Concomitant use of dual antiplatelet agents was associated with increased risk of GI bleeding in the rivaroxaban group (OR = 7.4, p = 0.0378). Prior GI bleeding was also a risk factor for GI bleeding in rivaroxaban group (OR = 15.5). Conclusion. The incidence of GI bleeding was similar between rivaroxaban and warfarin. The risk factors for GI bleeding with rivaroxaban were the first 40 days of taking the drug, concomitant dual antiplatelet agents, and prior GI bleeding.

UR - http://www.scopus.com/inward/record.url?scp=84961313958&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84961313958&partnerID=8YFLogxK

U2 - 10.1155/2016/9589036

DO - 10.1155/2016/9589036

M3 - Article

AN - SCOPUS:84961313958

VL - 2016

JO - Gastroenterology Research and Practice

JF - Gastroenterology Research and Practice

SN - 1687-6121

M1 - 9589036

ER -